ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Impact of body weight changes on adverse events and treatment outcomes during R-CHOP chemotherapy for non-Hodgkin's lymphoma.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe investigated whether weight fluctuations during rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP) chemotherapy affect adverse events and outcomes in patients with non-Hodgkin lymphoma (NHL).
methodsThis single-center retrospective study included 151 patients who received R-CHOP between April 2015 and March 2023 and grouped them by first-cycle weight loss ≥ 5% (Group 1) or < 5% (Group 2). Patient characteristics, adverse events, and outcomes were assessed using survival analysis and Cox regression models.
resultsOf the 151 patients, Group 1 (35.1%) showed higher rates of selected toxicities-particularly fatigue (83.0% vs. 68.4%, p = 0.04) and anemia (43.4% vs. 27.6%, p = 0.04)-than Group 2; other toxicities were non-significant on nominal, unadjusted tests. Early weight loss correlated with further weight changes (cycles 2-5: r = 0.61-0.78, p < 0.01) and was associated with shorter recurrence-free survival (RFS; HR: 1.844, p = 0.048). Female sex and an mGPS of 2 independently predicted early weight loss (adjusted OR [95% CI]: female sex: 2.98 [1.43-6.20]; p = 0.004; mGPS of 2: 3.14 [1.39-7.07], p = 0.006). In multivariable models, only high IPI remained independently associated with worse RFS (p = 0.010).
conclusionEarly weight loss during R-CHOP correlated with higher toxicity events and was univariably associated with shorter RFS; IPI was the key independent predictor of RFS after adjustment. Monitoring weight fluctuations potentially facilitates the identification of vulnerable patients and could guide timely interventions. These findings are exploratory and based on nominal, unadjusted comparisons; prospective confirmation is required.
Indexed as
Identifiers
41298907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.